Millipore Sigma Vibrant Logo

MAB1330 Anti-Collagen Type II Antibody, clone COLL-II

View Products on Sigmaaldrich.com
MAB1330
100 µL  
Recuperando precio...
No pudo obtenerse el precio
La cantidad mínima tiene que ser múltiplo de
Maximum Quantity is
Al finalizar el pedido Más información
Ahorró ()
 
Solicitar precio
Disponibilidad a confirmar
Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      Ofertas especiales

       

      Póngase en contacto con el Servicio de Atención al Cliente

      Descripción

      Replacement Information

      Ofertas especiales

      Tabla espec. clave

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      B, Ca, H, M, Po, R, ShELISA, IHCMAscitesMonoclonal Antibody
      Description
      Catalogue NumberMAB1330
      Brand Family Chemicon®
      Trade Name
      • Chemicon
      DescriptionAnti-Collagen Type II Antibody, clone COLL-II
      References
      Product Information
      FormatAscites
      HS Code3002 15 90
      Control
      • Cartilage in lung or fetus
      PresentationAscites fluid containing no preservatives.
      Quality LevelMQ100
      Applications
      ApplicationThis Anti-Collagen Type II Antibody, clone COLL-II is validated for use in ELISA, IH for the detection of Collagen Type II.
      Key Applications
      • ELISA
      • Immunohistochemistry
      Application NotesImmunofluorescence: 1:2-1:5 with fresh, frozen or acetone-fixed material. Mild pepsin digestion is recommended to enhance staining.

      Western Blot: 1:1000-1:2000 with chemiluminescent detection

      ELISA at 1:100-1:500, pepsin treated samples.





      Optimal working dilutions must be determined by the end user.
      Biological Information
      ImmunogenHuman (cartilage specific) CNBr-cleaved collagen II.
      CloneCOLL-II
      ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
      HostMouse
      SpecificityReacts with both pepsin-solubilized and CNBr-cleaved human and bovine collagen type II. No cross-reactivity with collagen types I, III, V and IX.
      IsotypeIgG1
      Species Reactivity
      • Bovine
      • Canine
      • Human
      • Mouse
      • Pig
      • Rat
      • Sheep
      Antibody TypeMonoclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryThis gene encodes the alpha-1 chain of type II collagen, a fibrillar collagen found in cartilage and the vitreous humor of the eye. Mutations in this gene are associated with achondrogenesis, chondrodysplasia, early onset familial osteoarthritis, SED congenita, Langer-Saldino achondrogenesis, Kniest dysplasia, Stickler syndrome type I, and spondyloepimetaphyseal dysplasia Strudwick type. In addition, defects in processing chondrocalcin, a calcium binding protein that is the C-propeptide of this collagen molecule, are also associated with chondrodysplasia. There are two transcripts identified for this gene.
      Gene Symbol
      • COL2A1
      • SEDC
      • COL11A3
      • ANFH
      • MGC131516
      • chondrocalcin
      • AOM
      Purification MethodUnpurified
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P02458 # Type II collagen is specific for cartilaginous tissues. It is essential for the normal embryonic development of the skeleton, for linear growth and for the ability of cartilage to resist compressive forces.
      SIZE: 1487 amino acids; 141785 Da
      SUBUNIT: Homotrimers of alpha 1(II) chains.
      SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular matrix (By similarity).
      TISSUE SPECIFICITY: High expression of isoform 2 in juvenile chondrocyte and low in fetal chondrocyte.
      PTM: Prolines at the third position of the tripeptide repeating unit (G-X-Y) are hydroxylated in some or all of the chains. & The N-telopeptide is covalently linked to the helical COL2 region of alpha 1(IX), alpha 2(IX) and alpha 3(IX) chain. The C- telopeptide is covalently linked to an another site in the helical region of alpha 3(IX) COL2.
      DISEASE: SwissProt: P02458 # Defects in COL2A1 are the cause of a variety of chondrodysplasia including hypochondrogenesis and osteoarthritis. & Defects in COL2A1 are the cause of spondyloepiphyseal dysplasia congenital type (SEDC) [MIM:183900]. This disorder is characterized by disproportionate short stature and pleiotropic involvement of the skeletal and ocular systems. & Defects in COL2A1 are the cause of Strudwick type spondyloepimetaphyseal dysplasia (SEMD) [MIM:184250]. SEMD is characterized by disproportionate short stature, pectus carinatum, and scoliosis, as well as dappled metaphyses (which is not seen in SEDC). & Defects in COL2A1 are the cause of achondrogenesis hypochondrogenesis type 2 (ACG2) [MIM:200610]. ACG2 is a disease characterized by the absence of ossification in the vertebral column, sacrum and pubic bones. & Defects in COL2A1 are the cause of Legg-Calve-Perthes disease (LCPD) [MIM:150600]; also known as Legg-Perthes disease or Perthes disease. LCPD is characterized by loss of circulation to the femoral head, resulting in avascular necrosis in a growing child. Clinical pictures of the disease vary, depending on the phase of disease progression through ischemia, revascularization, fracture and collapse, and repair and remodeling of the bone. & Defects in COL2A1 are the cause of Kniest syndrome (KS) [MIM:156550]; also known as Kniest dysplasia or metatropic dwarfism type II. KS is a moderately severe chondrodysplasia phenotype that results from mutations in the COL2A1 gene. Characteristics of the disorder include a short trunk and extremities, mid-face hypoplasia, cleft palate, myopia, retinal detachment, and hearing loss. & Defects in COL2A1 are a cause of primary avascular necrosis of femoral head (ANFH) [MIM:608805]; also called ischemic necrosis of the femoral head or osteonecrosis of the femoral head. ANFH causes disability that often requires surgical intervention. Most cases are sporadic, but families in which there is an autosomal dominant inheritance of the disease have been identified. It has been estimated that 300,000 to 600,000 people in the United States have ANFH. Approximately 15,000 new cases of this common and disabling disorder are reported annually. The age at the onset is earlier than that for osteoarthritis. The diagnosis is typically made when patients are between the ages of 30 and 60 years. The clinical manifestations, such as pain on exertion, a limping gait, and a discrepancy in leg length, cause considerable disability. Moreover, nearly 10 percent of the 500,000 total-hip arthroplasties performed each year in the United States involve patients with ANFH. As a result, this disease creates a substantial socioeconomic cost as well as a burden for patients and their families. & Defects in COL2A1 are the cause of osteoarthritis with mild chondrodysplasia [MIM:604864]. Osteoarthritis is a common disease that produces joint pain and stiffness together with radiologic evidence of progressive degeneration of joint cartilage. Some forms of osteoarthritis are secondary to events such as trauma, infections, metabolic disorders, or congenital or heritable conditions that deform the epiphyses or related structures. In most patients, however, there is no readily identifiable cause of osteoarthritis. Inheritance in a Mendelian dominant manner has been demonstrated in some families with primary generalized osteoarthritis. Reports demonstrate coinheritance of primary generalized osteoarthritis with specific alleles of the gene COL2A1, the precursor of the major protein of cartilage. & Defects in COL2A1 are the cause of platyspondylic lethal skeletal dysplasia Torrance type (PLSD-T) [MIM:151210]. Platyspondylic lethal skeletal dysplasias (PLSDs) are a heterogeneous group of chondrodysplasias characterized by severe platyspondyly and limb shortening. PLSD-T is characterized by varying platyspondyly, short ribs with anterior cupping, hypoplasia of the lower ilia with broad ischial and pubic bones, and shortening of the tubular bones with splayed and cupped metaphyses. Histology of the growth plate typically shows focal hypercellularity with slightly enlarged chondrocytes in the resting cartilage and relatively well-preserved columnar formation and ossification at the chondro-osseous junction. PLSD-T is generally a perinatally lethal disease, but a few long-term survivors have been reported. & Defects in COL2A1 are the cause of multiple epiphyseal dysplasia with myopia and conductive deafness (EDMMD) [MIM:132450]. Multiple epiphyseal dysplasia is a generalized skeletal dysplasia associated with significant morbidity. Joint pain, joint deformity, waddling gait, and short stature are the main clinical signs and symptoms. EDMMD is an autosomal dominant disorder characterized by epiphyseal dysplasia associated with progressive myopia, retinal thinning, crenated cataracts, conductive deafness. & Defects in COL2A1 are the cause of spondyloperipheral dysplasia (SPD) [MIM:271700]. SPD patients manifest short stature, midface hypoplasia, sensorineural hearing loss, spondyloepiphyseal dysplasia, platyspondyly and brachydactyly. & Defects in COL2A1 are the cause of Wagner syndrome type II (WS-II); a disease characterized by early-onset cataracts, lattice degeneration of the retina, and retinal detachment without involvement of monocular tissues. & Defects in COL2A1 are the cause of Stickler syndrome type 1 (STL1) [MIM:108300]; also known as vitreous type 1, or membranous vitreous type. STL1 is an autosomal dominant disorder characterized by progressive myopia beginning in the first decade of life, vitreo-retinal degeneration, retinal detachment, cleft palate, midfacial hypoplasia, osteoarthritis, and sensorineural hearing loss. & Defects in COL2A1 are a cause of autosomal dominant rhegmatogenous retinal detachment (DRRD) [MIM:609508]. RDD most frequently results from retinal tearing at the time of posterior vitreous detachment. Non-syndromic RRD can be inherited in a clearly dominant fashion, although in most of these cases, the genetic locus for the disorder is unknown. However, RRD is also a common feature of the type II collagenopathies (disorders due to mutations in the gene COL2A1) and some recent examples of mutations in this gene suggest that COL2A1 should be considered a candidate gene for dominant RRD (DRRD). & Of special interest are three different variants that replace arginine codons at positions 275, 719 and 989 in the triple-helical domain with codons for cysteine, an amino acid not normally found in the triple-helical domain of type II collagen from any species. They are of special interest, because they are the only amino acid substitutions in the triple-helical domain that replaces a Y-position amino acid and cause a disease phenotype. Also, they are recurrent in that they have been found in more than one unrelated individual.
      SIMILARITY: SwissProt: P02458 ## Belongs to the fibrillar collagen family. & Contains 1 VWFC domain.
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsMaintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
      Packaging Information
      Material Size100 µL
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      MAB1330 04053252726927

      Documentation

      Anti-Collagen Type II Antibody, clone COLL-II Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      Anti-Collagen Type II Antibody, clone COLL-II Certificados de análisis

      CargoNúmero de lote
      MOUSE ANTI-HUMAN TYPE II COLLAGEN MONOCLONAL ANTIBODY - 2135081 2135081
      MOUSE ANTI-HUMAN TYPE II COLLAGEN MONOCLONAL ANTIBODY - 2424676 2424676
      MOUSE ANTI-HUMAN TYPE II COLLAGEN - 3394233 3394233
      MOUSE ANTI-HUMAN TYPE II COLLAGEN - 3498547 3498547
      MOUSE ANTI-HUMAN TYPE II COLLAGEN - 3782372 3782372
      MOUSE ANTI-HUMAN TYPE II COLLAGEN -2607288 2607288
      MOUSE ANTI-HUMAN TYPE II COLLAGEN -2691428 2691428
      MOUSE ANTI-HUMAN TYPE II COLLAGEN -2780629 2780629
      MOUSE ANTI-HUMAN TYPE II COLLAGEN MONOCLONAL ANTIBODY 2960614
      MOUSE ANTI-HUMAN TYPE II COLLAGEN MONOCLONAL ANTIBODY 2886691

      Referencias bibliográficas

      Visión general referenciasPub Med ID
      Mesenchymal stem cells in rabbit meniscus and bone marrow exhibit a similar feature but a heterogeneous multi-differentiation potential: superiority of meniscus as a cell source for meniscus repair.
      Ding, Z; Huang, H
      BMC musculoskeletal disorders  16  65  2015

      Mostrar resumen
      25887689 25887689
      Alternative splicing targeting the hTAF4-TAFH domain of TAF4 represses proliferation and accelerates chondrogenic differentiation of human mesenchymal stem cells.
      Kazantseva, J; Kivil, A; Tints, K; Kazantseva, A; Neuman, T; Palm, K
      PloS one  8  e74799  2013

      Mostrar resumen
      24098348 24098348
      Human articular chondrocytes express multiple gap junction proteins: differential expression of connexins in normal and osteoarthritic cartilage.
      Mayan, MD; Carpintero-Fernandez, P; Gago-Fuentes, R; Martinez-de-Ilarduya, O; Wang, HZ; Valiunas, V; Brink, P; Blanco, FJ
      The American journal of pathology  182  1337-46  2013

      Mostrar resumen
      23416160 23416160
      Human tendon stem cells better maintain their stemness in hypoxic culture conditions.
      Zhang, J; Wang, JH
      PloS one  8  e61424  2013

      Mostrar resumen
      23613849 23613849
      Isolation and characterization of novel, highly proliferative human CD34/CD73-double-positive testis-derived stem cells for cell therapy.
      Choi, WY; Jeon, HG; Chung, Y; Lim, JJ; Shin, DH; Kim, JM; Ki, BS; Song, SH; Choi, SJ; Park, KH; Shim, SH; Moon, J; Jung, SJ; Kang, HM; Park, S; Chung, HM; Ko, JJ; Cha, KY; Yoon, TK; Kim, H; Lee, DR
      Stem cells and development  22  2158-73  2013

      Mostrar resumen
      23509942 23509942
      Bilayered constructs aimed at osteochondral strategies: the influence of medium supplements in the osteogenic and chondrogenic differentiation of amniotic fluid-derived stem cells.
      Márcia T Rodrigues,Sang Jin Lee,Manuela E Gomes,Rui L Reis,Anthony Atala,James J Yoo,M Rodrigues
      Acta biomaterialia  8  2011

      Mostrar resumen
      22510402 22510402
      Epithelial cell rests of Malassez contain unique stem cell populations capable of undergoing epithelial-mesenchymal transition.
      Xiong, J; Mrozik, K; Gronthos, S; Bartold, PM
      Stem cells and development  21  2012-25  2011

      Mostrar resumen
      22122577 22122577
      Advanced glycation end products cause collagen II reduction by activating Janus kinase/signal transducer and activator of transcription 3 pathway in porcine chondrocytes.
      Huang, CY; Lai, KY; Hung, LF; Wu, WL; Liu, FC; Ho, LJ
      Rheumatology (Oxford, England)  50  1379-89  2010

      Mostrar resumen
      21482542 21482542
      Preservation of the chondrocyte's pericellular matrix improves cell-induced cartilage formation.
      Lucienne A Vonk,Behrouz Zandieh Doulabi,Chunling Huang,Marco N Helder,Vincent Everts,Ruud A Bank
      Journal of cellular biochemistry  110  2009

      Mostrar resumen
      20213765 20213765
      Human mesenchymal stem cell culture for neural transplantation.
      David Gordon, Neil J Scolding, David Gordon, Neil J Scolding, David Gordon, Neil J Scolding
      Methods in molecular biology (Clifton, N.J.)  549  103-18  2009

      Mostrar resumen
      19378199 19378199

      Productos y aplicaciones relacionados

      Related Products

      Número de referencia Descripción  
      AB746P Anti-Collagen Type II Antibody Precios y disponibilidad
      AB761 Anti-Collagen Type II Antibody Precios y disponibilidad
      MAB8887 Anti-Collagen Type II Antibody, clone 6B3 Precios y disponibilidad

      Familias de productos

      Categorías

      Life Science Research > Antibodies and Assays > Primary Antibodies